Abstract: Oligomers can be prepared from bicyclic nucleoside. The nucleosides can be a compound of formula (I) in which each of T1 and T2 is independently OR1 or OR2; R1 is H or a hydroxyl protecting group, R2 is a phosphorus moiety; and Bx is a nucleobase. The compounds, bicyclic nucleosides and the oligomers are useful for the prevention, treatment or diagnosis of muscular dystrophy.

Abstract: Anti-BK virus antibody molecules or binding fragments thereof are disclosed. These Anti-BK virus antibody molecules or binding fragments can be used in the treatment or prevention of BK virus infection and/or BK virus associated disorder.

Abstract: The present invention relates to a magnetic field exposure system for use in exposing organic cells, cellular tissue or at least a part of a subject to a low frequency magnetic field. The system includes a magnetic field generator and amplifier feeding one or more electromagnetic coils configured to produce a magnetic field that varies according to an amplitude modulated signal with a carrier frequency of from 360 to 450. Hz, wherein the modulation frequency is from 0.5 to 100. Hz; and wherein the MF has a field strength of from 0.5 to 250 ?T.

Abstract: The invention relates to nucleic acid products that interfere with or inhibit PROS1 gene expression. It further relates to therapeutic uses of PROS1 inhibition for the treatment of bleeding disorders.

Abstract: Provided herein is an inositol polyphosphate oligo alkyl ether compound, or its pharmaceutically acceptable salt, for use in treatment or prevention of a disease associated with formation of calcium salt crystals.

Abstract: The invention provides an siRNA against protein S for use in a method of treatment of hemophilia. Also within the scope of the present invention is a method for treating hemophilia in a patient in need thereof, comprising administering to the patient a molecule comprising a siRNA according to the invention, and a dosage form for the prevention or treatment of hemophilia, comprising a molecule comprising a siRNA according to the invention.

Abstract: The invention is related to an inositol polyphosphate oligo alkyl ether compound, or its pharmaceutically acceptable salt, for use in treatment or prevention of a disease associated with formation of calcium salt crystals.

Abstract: A cell culturing system includes a docking station, a handling unit, a culturing module and an actuation layer. The culturing module has a culturing well and a culturing membrane separating the culturing well in an apical culturing chamber and a basal culturing chamber. The handling unit removably accommodates the culturing module and the actuation layer. The docking station has a coupling structure for removably holding the handling unit in a predefined position and an actuation feeding channel, wherein, when the handling unit is held by the coupling structure in the predefined position, a first end of the actuation feeding channel is connected to the actuation bore and a second end of the actuation feeding channel is connected to a connector.

Abstract: The invention relates to a method for obtaining a visual field map of an observer, particularly a perimetry method, wherein a plurality of test locations in front of the observer is provided, at each test location of a subset of said plurality a respective perceived sensitivity threshold 5 is measured, wherein at least one light signal is provided at the respective test location, and wherein it is monitored whether said observer observes said at least one light signal, and wherein for each test location a respective estimate of the perceived sensitivity threshold is derived from the previously measured perceived sensitivity thresholds of said subset, and wherein said light signal is provided at a light intensity value derived from the estimate of the 10 perceived sensitivity threshold of said respective test location.

Abstract: The invention relates to nucleic acid products that interfere with or inhibit PROS1 gene expression. It further relates to therapeutic uses of PROS1 inhibition for the treatment of bleeding disorders.

Abstract: The present invention relates to compounds of formula 1 or 2, wherein R1 and R3 are purine or a purine analog and R2 and R4 are a small functional group. The invention also relates to intermediates of the synthesis of compounds of formula 1 or 2. Compounds of formula 1 or 2 are Janus kinase inhibitors and thus useful in the treatment of a disease, particularly an autoimmune disease, cancer, Alzheimer's disease or useful in preventing the rejection of an allograft or xenograft.

Abstract: The invention relates to stereoselective peptide dendrimers for nucleic acid transfection comprising the formula (D3)8-(B3-D2)4-(B2-D1)2-B1—Z (1), wherein Z is a hydrophobic core with Z being —XY1 (1a), —XY2XY2 (1b), —XY3Cys (1c) or —HP (1d), X is selected from Lys or Glu, and each Y is fatty or amine acids, HP is a hydrophobic peptide consisting of 3 to 5 hydrophobic amino, B is Lys and each D independently from any other D is a dipeptide consisting of one hydrophobic amino acid and one cationic amino acid (HC or CH), a dipeptide consisting of two cationic amino acids (CC) or a dipeptide consisting of two hydrophobic amino acids (HH). The invention further comprises a method for transfecting a cell (ex vivo) using the above-mentioned dendrimer.

Abstract: A device for in-vitro modelling in-vivo tissues of organs that includes a first body portion with at least one access chamber, a second body portion with at least one culturing chamber, and a culturing membrane dividing the at least one access chamber from the culturing chamber. The device further includes a third body portion with at least one actuation chamber having at least one limitation cavity, and an actuation membrane dividing the at least one culturing chamber from the at least one actuation chamber. With the device, a robust actuation system can be provided that does not depend on the mechanical properties of the actuation membrane material, nor on the pressure, and that allows to mimic three-dimensional deformations of the tissue, in particular of lung alveoli.

Abstract: The invention relates to a method for obtaining a visual field map of an observer, particularly a perimetry method, wherein a plurality of test locations in front of the observer is provided, at each test location of a subset of said plurality a respective perceived sensitivity threshold is measured, wherein at least one light signal is provided at the respective test location, and wherein it is monitored whether said observer observes said at least one light signal, and wherein for each test location a respective estimate of the perceived sensitivity threshold is derived from the previously measured perceived sensitivity thresholds of said subset, and wherein said light signal is provided at a light intensity value derived from the estimate of the perceived sensitivity threshold of said respective test location.

Abstract: An aspect of the invention provides a method and a product for determining a modification of the therapy management by using a processor unit which retrieves few data related to the blood glucose measurement performed over a predetermined time period; retrieve the medication delivery parameter executed by the delivery device over said predetermined time period; retrieve from the memory data associated to the CIR of the patient; and determine a modification to the therapy based on at least a part of the retrieved data.

Abstract: The invention relates to nucleic acid products that interfere with PROS1 gene expression or inhibit its expression. The nucleic acids are particularly for use in the treatment, prevention or reduction of risk of suffering from a bleeding disorder.

Abstract: The invention relates to nucleic acid products that interfere with or inhibit PROS1 gene expression. It further relates to therapeutic uses of PROS1 inhibition for the treatment of bleeding disorders.

Abstract: The invention relates to an implantable valve (1) for a drainage system for discharging cerebrospinal fluid, comprising: a valve housing (10) extending along a valve axis (A), an inlet (2) and an outlet (3) as well as a valve housing (10) surrounding an interior space (4), a valve body assembly (600) arranged in the interior (4) and movably arranged in the interior space (4), a first valve seat (5), wherein the valve body assembly (600) is configured to abut the first valve seat (5) to close a flow connection between the inlet (2) and the interior space (4) of the valve housing (10), a second valve seat (7) which faces the first valve seat (5), wherein the valve body assembly (600) is configured to abut the second valve seat (7) to close a flow connection between the outlet (3) and the interior space (4) of the valve housing (10), and a spring device (800) arranged in the interior space (4) which exerts a spring force on the valve body assembly (600) in the direction of the first valve seat (5).

Abstract: The present invention relates to a nanosphere comprising an equal number of a human SEC14-like protein and a cognate ligand of said SEC14-like protein as well as to methods of producing the same and uses of said nanospheres.

Abstract: The present invention relates to compositions, immunogenic or vaccine compositions and pharmaceutical compositions for the prevention or treatment of a condition or disorder selected from a pruritic condition or an allergic condition, of equine mammals, preferably of horses. Furthermore, the invention provides methods for preventing or treating pruritus, preferably pruritus associated with a pruritic condition or an allergic condition such as allergic dermatitis, of equine mammals, preferably of horses.